ArticleBioengineering (Basel, Switzerland)2021
CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics.
Article in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Approaching Gold-Standard Sensitivity in a Portable and Versatile Gold Nanoprisms Thermoplasmonic Platform for Lateral Flow Detection of Biomolecules.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A smartphone-powered decentralized microfluidic platform for sensitive CRISPR-based nucleic acid detection.Microsystems & nanoengineering · 2026Article
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- A comprehensive review of lateral flow assays in rapid livestock and poultry disease diagnostics.Journal of advanced veterinary and animal research · 2026Article
- An overview of CRISPR-artificial intelligence theranostics: Current and emerging applications.Biomaterials translational · 2026Review
- CRISPR-Cas12 Application for the Detection ofInternational journal of molecular sciences · 2025Article
- Advancements and Applications of Lateral Flow Assays (LFAs): A Comprehensive Review.Sensors (Basel, Switzerland) · 2025Review
- CRISPR for companion diagnostics in low-resource settings.Lab on a chip · 2024Review
- Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care.ACS omega · 2023Review
- CRISPR/Cas9 Landscape: Current State and Future Perspectives.International journal of molecular sciences · 2023Review
- Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2.The CRISPR journal · 2023Article
- A Lateral Flow Assay for the Detection ofSensors (Basel, Switzerland) · 2023Article
- Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
- SARS-CoV-2 Diagnostics Based on Nucleic Acids Amplification: From Fundamental Concepts to Applications and Beyond.Frontiers in cellular and infection microbiology · 2022Review
- A Sensitive, Portable Microfluidic Device for SARS-CoV-2 Detection from Self-Collected Saliva.Infectious disease reports · 2021Article
- Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics.Life (Basel, Switzerland) · 2021Review
- Paper-Based Biosensors for COVID-19: A Review of Innovative Tools for Controlling the Pandemic.ACS omega · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Clustered regularly interspaced short palindromic repeat (CRISPR/Cas) proteins can be designed to bind specified DNA and RNA sequences and hold great promise for the accurate detection of nucleic acids for diagnostics. We integrated commercially available reagents into a CRISPR/Cas9-based lateral flow assay that can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences with single-base specificity. This approach requires minimal equipment and represents a simplified platform for field-based deployment. We also developed a rapid, multiplex fluorescence CRISPR/Cas9 nuclease cleavage assay capable of detecting and differentiating SARS-CoV-2, influenza A and B, and respiratory syncytial virus in a single reaction. Our findings provide proof-of-principle for CRISPR/Cas9 point-of-care diagnosis as well as a scalable fluorescent platform for identifying respiratory viral pathogens with overlapping symptomology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.